Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News SCYNEXIS Inc SCYX

Healthcare Drug Manufacturers - Specialty & Generic
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the... see more

Current News (NDAQ:SCYX)

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

GlobeNewswire 9 days ago

SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247

GlobeNewswire February 26, 2026

SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)

GlobeNewswire January 28, 2026

SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247

GlobeNewswire January 21, 2026

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

GlobeNewswire December 22, 2025

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

GlobeNewswire November 19, 2025

Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections

GlobeNewswire November 17, 2025

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 5, 2025

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

GlobeNewswire October 15, 2025
View More News ››

Opinion & Analysis (NDAQ:SCYX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:SCYX)

RE:RE:wtf?

They sold the drug, not the company. Too bad, I wish they had sold the entire company.  I guess this useless management team gets...
JonathanJSmith - March 31, 2023

RE:wtf?

Great timing Mr. Smith...... Care to stick your other foot in your mouth?? Don't quit ur day job !
Iseneschal - March 30, 2023

wtf?

What happened to these guys? What a disgrace. Fire the entire management team and start anew. Sell this company for what can be salvaged...
JonathanJSmith - March 16, 2023

Can we expect additional Rx's to the fold this winter?

It's been a while and I've had some time to digest several variables; here are some of my findings: These guys are still trading...
JonathanJSmith - August 2, 2022

RE:RE:RE:RE:BREXAFEMME - published User side effects

I'm disgusted too. What does $45MM get them, another quarter's worth of financing - maybe two? One would think that they'd...
JonathanJSmith - April 26, 2022

RE:RE:RE:BREXAFEMME - published User side effects

I was going to sell at a loss, but decided to lower my average cost due to the discount. They will have $150M cash less Q1 spend...
dmacd - April 22, 2022
View more Bullboard ››

Silver North Resources Ltd.

Silver North Resources Ltd.

Silver North Resources Ltd., an exploration stage company, acquires and explores mineral properties. It explores for gold ...
View More »

Podcasts